Company profile: ALX Oncology
1.1 - Company Overview
Company description
- Provider of preclinical-stage immuno-oncology therapies for cancer, including Evorpacept (ALX148), a next-generation CD47 blocking therapeutic with high affinity for CD47 and designed to avoid hematologic toxicities, used in combination with anti-cancer agents to enhance immune activation and treat various cancers.
Products and services
- Evorpacept (ALX148): A high-affinity CD47-blocking therapeutic engineered to avoid hematologic toxicities, used with anti-cancer agents to enhance immune activation and treat various cancers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ALX Oncology
Nuvation Bio
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical therapies addressing unmet needs, developing oral targeted candidates including Taletrectinib (CNS-active, selective next-generation ROS1 inhibitor for ROS1-positive NSCLC), Safusidenib (potent mIDH1 inhibitor for grades 2-3 IDH1-mutant glioma), NUV-868 (BD2-selective BET inhibitor targeting BRD4), and NUV-1511 (drug-drug conjugate candidate).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvation Bio company profile →
Oncimmune
HQ: United Kingdom
Website
- Description: Provider of proprietary autoantibody assay technologies for early cancer detection, offering ImmunoINSIGHTS analytical platform to discover and profile autoantibody biomarkers for disease characterization, patient stratification, and response prediction; biomarker discovery services; customizable targeted panels and arrays for immuno-oncology and autoimmune diseases; and bioinformatics and data science with multiomics integration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncimmune company profile →
Freenome
HQ: United States
Website
- Description: Provider of blood-based tests and clinical studies for early cancer detection to improve access to routine screening, including PREEMPT CRC for colorectal cancer and the PROACT LUNG study using a blood test. Runs the Vallania and Sanderson studies targeting multiple cancers, pairing real-world data with multiomics; partners with Walgreens to increase research diversity; and acquired Oncimmune Ltd to enhance its cancer detection portfolio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freenome company profile →
Tusk Therapeutics
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapies, discovering and developing unique therapeutic antibodies that harness the immune system to treat cancer, with a growing, diversified pipeline targeting both novel and validated targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tusk Therapeutics company profile →
Complix
HQ: Belgium
Website
- Description: Provider of Alphabody biopharmaceuticals focused on discovering and developing a novel class of therapeutics that bind with high affinity to disease targets. Offerings include Cell Penetrating Alphabodies to modulate intracellular protein interactions, a pipeline for intracellular targets in cancer, autoimmunity, and viral diseases, and anti-Covid-19 Alphabodies targeting SARS-CoV-2 fusion for prophylactic and therapeutic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Complix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ALX Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ALX Oncology
2.2 - Growth funds investing in similar companies to ALX Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ALX Oncology
4.2 - Public trading comparable groups for ALX Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →